WO1992015581A1 - PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES - Google Patents

PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES Download PDF

Info

Publication number
WO1992015581A1
WO1992015581A1 PCT/US1992/001212 US9201212W WO9215581A1 WO 1992015581 A1 WO1992015581 A1 WO 1992015581A1 US 9201212 W US9201212 W US 9201212W WO 9215581 A1 WO9215581 A1 WO 9215581A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
group
alkyl
phenyl
substituted
Prior art date
Application number
PCT/US1992/001212
Other languages
French (fr)
Inventor
John F. Gerster
Original Assignee
Minnesota Mining And Manufacturing Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining And Manufacturing Company filed Critical Minnesota Mining And Manufacturing Company
Priority to DE69213720T priority Critical patent/DE69213720T2/en
Priority to EP92909690A priority patent/EP0575549B1/en
Priority to JP50932392A priority patent/JP3313708B2/en
Priority to AU16993/92A priority patent/AU657958B2/en
Priority to KR1019930702603A priority patent/KR100226184B1/en
Priority to CA002104781A priority patent/CA2104781C/en
Publication of WO1992015581A1 publication Critical patent/WO1992015581A1/en
Priority to NO933105A priority patent/NO301714B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • This invention relates to processes and intermediates for preparing 1H-imidazo[4,5-c]-quinolines. In another aspect this invention relates to processes and intermediates for preparing
  • This invention provides a process for
  • step (iii) hydrolysing the product of step (ii) to afford a 1H-imidazo[4,5-c]quinolin-4-amine;
  • step (iv) isolating the product of step (iii) or a pharmaceutically acceptable acid-addition salt thereof.
  • This invention also provides a process for preparing a compound of Formula I
  • R 1 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
  • R 2 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and wherein R a and R b are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon
  • R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:
  • R, n, and R 2 are as defined above with the proviso that Z in R 2 is other than amino, substituted amino, or hydroxy, and R 5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and
  • substituted straight chain or branched chain alkyl containing one to about ten carbon atoms wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms;
  • alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms
  • acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms
  • step (iii) hydrolysing the product of step (ii) to provide a compound of Formula I;
  • step (iv) optionally converting or further elaborating the group Z in R 2 ; and (v) isolating the compound of Formula I from step (iv) or a pharmaceutically acceptable acid addition salt thereof.
  • This invention also provides intermediate compounds of Formula III above and a process for preparing such intermediates.
  • the Reaction Scheme begins with a 4-hydroxyquinoline of Formula IV.
  • Many 4-hydroxyquinolines of Formula IV are commercially available. The others are known and/or can be prepared readily by those skilled in the art.
  • Step 1 involves nitration of a 4-hydroxyquinoline to provide a 3-nitro-4-hydroxyquinoline of Formula V.
  • step 2 a 3-nitro-4-hydroxyquinoline is chlorinated at the 4-position to provide a 3-nitro-4- chloroquinoline of Formula VI.
  • Step 2 can be carried out by reacting a compound of Formula V in an inert solvent (e.g., methylene
  • chloride with a chlorinating agent (e.g., phosphorus oxychloride).
  • a chlorinating agent e.g., phosphorus oxychloride.
  • Step 3 involves reacting a compound of
  • step 3 The reaction of step 3 is preferably carried out in the presence of a tertiary amine catalyst (such as triethylamine), and it is preferred to run the reaction without isolation of the chloro compound from step 2.
  • a tertiary amine catalyst such as triethylamine
  • Step 4 involves several reactions including: (i) reduction of the nitro group of the compound of Formula VII, and (ii) reaction of the resulting 3-amino compound with a carboxylic acid or an equivalent thereof in order to provide a cyclized
  • step (4) is preferably carried out using a conventional heterogeneous
  • hydrogenation catalyst such as platinum on carbon.
  • the reduction can be carried out conveniently on a Paar apparatus in an inert solvent such as toluene, ethyl acetate, or a lower alkanol.
  • a 3-amino compound is reacted with (a) a 1,1-dialkoxyalkyl alkanoate such as diethoxymethyl acetate, or (b) a carboxylic acid that will introduce the desired R 2 group, or (c) a trialkyl ortho ester of the formula R 2 C(Oalkyl) 3 , wherein "alkyl” is an alkyl group containing one to about four carbon atoms, or (d) a combination of such a carboxylic acid with such a trialkyl ortho ester to provide an
  • the reaction can be carried out by heating, e.g., at about 130°C, in the presence of an acid, preferably an alkanoic acid having one more carbon atom than R 2 .
  • part (ii) of step 4 also involves protecting the hydroxyl group with a removable protecting group such as an alkanoyloxy group (e.g., acetoxy) or an aroyloxy group (e.g., benzoyloxy).
  • a removable protecting group such as an alkanoyloxy group (e.g., acetoxy) or an aroyloxy group (e.g., benzoyloxy).
  • the protecting group can later be removed as appropriate when it will no longer interfere with subsequent reactions.
  • Part (iii) of step (4) provides an intermediate of Formula II.
  • the quinoline nitrogen is oxidized with a conventional oxidizing agent that is capable of forming N-oxides.
  • Preferred oxidizing agents include peroxyacids (such as peroxyacetic acid) and hydrogen peroxide.
  • Preferred conditions involve mild heating (e.g., at about 50°C-60°C) in an ethanolic solution of peroxyacetic acid.
  • Step (5) involves: (a) reacting a compound of Formula II with an isocyanate to afford an intermediate of Formula III; (b) hydrolysing the intermediate; (c) optionally converting or further elaborating the group Z in R 2 ; and (d) isolating the compound of Formula I from step (d) or a pharmaceutically acceptable acid addition salt thereof.
  • Part (a) of step (5) involves reacting an N-oxide with an isocyanate wherein the isocyanato group is bonded to a hydrolytically active functional group.
  • hydrolytically active functional group designates any functional group that is capable of being subjected to a nucleophilic
  • hydrolytically active functional groups include carbonyl
  • a particular class of such isocyanates is isocyanates of the formula R i -X-NCO, wherein R i is an organic group substantially inert to quinoline N-oxides under the conditions of step (5) (a) and X is a hydrolytically active functional group.
  • Suitable R i groups are easily selected by those skilled in the art.
  • Preferred groups R i include alkyl, aryl, alkenyl, and combinations thereof.
  • Particular preferred isocyanates include aroyl isocyanates such as benzoyliso ⁇ yanate.
  • the reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as dichloromethane. The resulting
  • 4-substituted compound of Formula III can be isolated by removal of the solvent.
  • Step (5) (b) of the Reaction Scheme involves hydrolysis of a compound of Formula III.
  • the term "hydrolysis” as used herein designates not only
  • reaction can be carried out by general methods well known to those skilled in the art, e.g., by heating in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a nucleophilic solvent such as
  • a hydroxyl-containing compound of Formula I can be converted or further elaborated by methods well known to those skilled in the art to afford a further compound of Formula I.
  • reaction with thionyl chloride will provide a compound of Formula I wherein Z is chloro.
  • a nucleophile such as sodium azide, pyrrolidine,
  • Some compounds of Formula I can be prepared by a similar reaction scheme wherein the final desired group Z is introduced directly in step (4) and carried on through the process of the invention.
  • the product compound of Formula I can be isolated by the conventional means disclosed in U.S. Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, or by dissolution in an appropriate solvent (e.g., methanol) and re-precipitation by addition of a second solvent in which the compound is insoluble.
  • an appropriate solvent e.g., N,N-dimethylformamide
  • solvent mixture e.g., methanol
  • the compounds of Formula I can be used in the form of acid addition salts such as hydrochlorides, dihydrogen sulfates, trihydrogen phosphates, hydrogen nitrates, methane sulfonates and salts of other
  • Pharmaceutically acceptable acid-addition salts of compounds of Formula I are generally prepared by reaction of the respective compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e.g., diethyl ether).
  • a solvent in which the salt e.g., diethyl ether
  • N,N-dimethylformamide (8.5 mL, 0.11 mol) were added.
  • the reaction mixture was then heated for 3.5 hours at reflux, during which time a small amount of solid precipitated.
  • the reaction mixture was then cooled to -15°C and a solution of isobutylamine (15.1 mL, 0.15 mol), and triethylamine (20.9 mL, 0.15 mol) in
  • dichloromethane 100 mL was added in a slow stream with vigorous swirling. During the addition the temperature of the reaction mixture rose to 20°C. The resulting solution was heated at reflux for 30 minutes, cooled, and the solvent was removed at reduced pressure to afford a yellow solid product. The product was slurried in water, filtered, washed with water, and dried partially. The partially dried product was then slurried in ethanol (75 mL), filtered, washed
  • N-(2-methylpropyl)-3-nitro-4-quinolinamine (61.3 g, 0.25 mol) was placed in a Paar apparatus along with 5% Pt/C (1.5 g), magnesium sulfate (60 g), ethyl acetate (750 mL), and formic acid (400 mL).
  • N-Benzoyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (5.0 g, 0.0145 mol) and sodium methoxide (10 drops of a 25% by weight solution in methanol) were mixed in methanol (50 mL) and the mixture was heated at reflux for 75 minutes. The mixture was cooled to room temperature, and a solid formed. The solid was filtered from the mixture, washed sequentially with water and methanol, and dried. A crude yield of colorless product of 3.3 g (94.3%) was obtained. Spectral properties of the product
  • 3-Amino-4-(2-methylpropylamino)quinoline (43.5 g; 0.20 mole) and 300 mL of formic acid were combined and heated on a steam bath for several hours.
  • the reaction mixture was concentrated under vacuum, diluted with water, basified with ammonium hydroxide then extracted twice with ether.
  • the ether extracts were treated with activated charcoal then combined for a total volume of 1200 mL. The volume was reduced to 500 mL, cooled, then filtered to provide 31.1 g of a light green crystalline solid 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline.
  • n-butyl lithium 2.5 M in hexanes
  • benzaldehyde 2.7 mL; 0.027 mole
  • the reaction mixture was allowed to warm slightly.
  • the reaction was quenched with water then diluted with ethyl ether.
  • the ether was separated, dried with magnesium sulfate then concentrated under vacuum.
  • the resulting residue was purified by silica gel

Abstract

A process and intermediates for preparing 1-substituted-1H-imidazo[4,5-c]quinolin-4-amines. The process involves reacting a 1-substituted-1H-imidazo[4,5-c]quinoline-5N-oxide with an isocyanate and hydrolysing the product thereof. Also, a process for preparing the intermediates is disclosed.

Description

PROCESS FOR IMIDAZO[4,5-C]QUINOLIN-4-AMINES
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to processes and intermediates for preparing 1H-imidazo[4,5-c]-quinolines. In another aspect this invention relates to processes and intermediates for preparing
1-substituted-1H-imidazo[4,5-c]quinolin-4-amines.
Description of the Related Art
The synthesis of 1H-imidazo[4,5-c]quinolin-4-amines has been described in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.). The methods described therein involve the step of heating the
4-chloro compound in the presence of ammonium hydroxide or ammonia under pressure (e.g., in a sealed reactor) to afford the 4-amino compound.
The reaction of phenyl isocyanate with heteroaromatic 6-membered ring N-oxides has been reported in "Organic Chemistry: A series of
Monographs, Chemistry of the Heterocyclic N-oxides." A. R. Katritsky and J. Lagowski. Alfred T. Bloomquist, Ed., Academic Press, 1971. The reaction is said to afford the α-anilino derivative.
SUMMARY OF THE INVENTION
This invention provides a process for
preparing a 1H-imidazo[4,5-c]quinolin-4-amine,
comprising the steps of:
(i) providing a 1H-imidazo[4,5-c]quinoline 5N-oxide having no functional groups other than the 5N-oxide that are reactive to organic isocyanates;
(ii) reacting the 1H-imidazo[4,5-c]quinoline
5N-oxide from step (i) with an organic isocyanate of the formula Ri-X-NCO, wherein Ri is an organic group substantially inert to quinoline N-oxides and X is a hydrolytically active functional group, to afford a 1H-imidazo[4,5-c]quinoline having a 4-substituent of the formula Ri-X-NH-;
(iii) hydrolysing the product of step (ii) to afford a 1H-imidazo[4,5-c]quinolin-4-amine; and
(iv) isolating the product of step (iii) or a pharmaceutically acceptable acid-addition salt thereof.
This invention also provides a process for preparing a compound of Formula I
Figure imgf000004_0001
wherein
R1 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
R2 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000005_0001
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, chloro, hydroxy,
1-morpholino, 1-pyrrolidino, and thioalkyl of one to about four carbon atoms;
R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and n is zero or one; or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:
(i) providing a compound of Formula II
Figure imgf000006_0001
wherein R, n, and R2 are as defined above with the proviso that Z in R2 is other than amino, substituted amino, or hydroxy, and R5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and
substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms;
straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is
substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
(ii) reacting the compound of Formula II with an isocyanate of the formula Ri-X-NCO, wherein X is a hydrolytically active functional group and Ri is an organic group substantially inert to quinoline N-oxides to afford an intermediate of Formula III
Figure imgf000007_0001
wherein X, Ri, R, R2, R5, and n are as defined above with the proviso that Z in R2 is other than amino,
substituted amino, or hydroxy;
(iii) hydrolysing the product of step (ii) to provide a compound of Formula I;
(iv) optionally converting or further elaborating the group Z in R2; and (v) isolating the compound of Formula I from step (iv) or a pharmaceutically acceptable acid addition salt thereof.
This invention also provides intermediate compounds of Formula III above and a process for preparing such intermediates.
The processes of this invention allow an N-oxide of Formula II to be aminated directly without chlorination and subsequent use of the high pressure conditions used in previous syntheses of
imidazo[4,5-c]quinolin-4-amines.
DETAILED DESCRIPTION OF THE INVENTION
For the purpose of the instant specification and claims, the term "lower" when used in connection with "alkyl" or "alkoxy" designates straight chain or branched chain groups containing one to about four carbon atoms.
The process of this invention is illustrated in the Reaction Scheme below, wherein X, Ri, R, n, R1, R2, and R5 are as defined above.
Figure imgf000009_0001
The Reaction Scheme begins with a 4-hydroxyquinoline of Formula IV. Many 4-hydroxyquinolines of Formula IV are commercially available. The others are known and/or can be prepared readily by those skilled in the art. Step 1 involves nitration of a 4-hydroxyquinoline to provide a 3-nitro-4-hydroxyquinoline of Formula V.
Conventional conditions for such reactions are well known. Preferred conditions in the instance where n is zero, which afford a product of Formula V in superior yield compared with conditions used in the prior art, involve heating at about 125°C-130°C in propionic acid in the presence of nitric acid. Preferred conditions in other instances will depend upon the particular 4-hydroxyquinoline used in step 1, and those skilled in the art will be able to select suitable conditions.
In step 2, a 3-nitro-4-hydroxyquinoline is chlorinated at the 4-position to provide a 3-nitro-4- chloroquinoline of Formula VI. Some compounds of
Formula VI are known and disclosed, e.g., in U.S. Pat. No. 3,700,674 (Diehl et al.) and references cited therein, and U.S. Pat. No. 4,689,338 (Gerster), both patents. The others can be prepared as shown in step 2. Step 2 can be carried out by reacting a compound of Formula V in an inert solvent (e.g., methylene
chloride) with a chlorinating agent (e.g., phosphorus oxychloride). Preferred conditions involve
chlorination in methylene chloride with a Vilsmeier reagent prepared from thionyl chloride and
N,N-dimethylformamide. In such a reaction, the
compound of Formula V is suspended in methylene
chloride, and a slight molar excess of thionyl chloride and N,N-dimethylformamide is added to the suspension. Heating to reflux facilitates the chlorination.
Step 3 involves reacting a compound of
Formula VI in an inert solvent with an amine of the formula R1NH2 to provide a compound of Formula VII.
Some compounds of Formula VII are disclosed in U.S.
Pat. No. 4,689,338 (Gerster). The others can be prepared as shown in step 3. The reaction of step 3 is preferably carried out in the presence of a tertiary amine catalyst (such as triethylamine), and it is preferred to run the reaction without isolation of the chloro compound from step 2.
Step 4 involves several reactions including: (i) reduction of the nitro group of the compound of Formula VII, and (ii) reaction of the resulting 3-amino compound with a carboxylic acid or an equivalent thereof in order to provide a cyclized
imidazo [4,5-c]quinoline.
The reduction in step (4) is preferably carried out using a conventional heterogeneous
hydrogenation catalyst such as platinum on carbon. The reduction can be carried out conveniently on a Paar apparatus in an inert solvent such as toluene, ethyl acetate, or a lower alkanol.
In part (ii) of step 4, a 3-amino compound is reacted with (a) a 1,1-dialkoxyalkyl alkanoate such as diethoxymethyl acetate, or (b) a carboxylic acid that will introduce the desired R2 group, or (c) a trialkyl ortho ester of the formula R2C(Oalkyl)3, wherein "alkyl" is an alkyl group containing one to about four carbon atoms, or (d) a combination of such a carboxylic acid with such a trialkyl ortho ester to provide an
imidazo [4,5-c]-quinoline. The reaction can be carried out by heating, e.g., at about 130°C, in the presence of an acid, preferably an alkanoic acid having one more carbon atom than R2.
An alternative to part (ii) of step 4
involves a reaction similar to that described above but involving formic acid or a trialkylorthoformate to form a 2-hydrogen substituted intermediate
1H-imidazo[4,5-c]quinoline. This compound is then deprotonated at the 2-position by a strong base (e.g., an alkyllithium such as n-butyllithium) and reacted with a compound of the formula
Figure imgf000012_0001
In instances wherein a primary or secondary hydroxyl group is present in the cyclized compound, part (ii) of step 4 also involves protecting the hydroxyl group with a removable protecting group such as an alkanoyloxy group (e.g., acetoxy) or an aroyloxy group (e.g., benzoyloxy). The protecting group can later be removed as appropriate when it will no longer interfere with subsequent reactions. Suitable
protecting groups and reactions for their placement and removal are well known to those skilled in the art. See, for example, U.S. Pat. No. 4,689,338 (Gerster), Examples 115-123.
Part (iii) of step (4) provides an intermediate of Formula II. The quinoline nitrogen is oxidized with a conventional oxidizing agent that is capable of forming N-oxides. Preferred oxidizing agents include peroxyacids (such as peroxyacetic acid) and hydrogen peroxide. Preferred conditions involve mild heating (e.g., at about 50°C-60°C) in an ethanolic solution of peroxyacetic acid.
Some compounds of Formula II are disclosed in U.S. Pat. Nos. 4,689,338 and 4,698,348 (Gerster). The others can be prepared as described in connection with step 4 herein.
A 1H-imidazo[4,5-c]quinolin-4-amine is prepared in step (5) of the Reaction Scheme. Step (5) involves: (a) reacting a compound of Formula II with an isocyanate to afford an intermediate of Formula III; (b) hydrolysing the intermediate; (c) optionally converting or further elaborating the group Z in R2; and (d) isolating the compound of Formula I from step (d) or a pharmaceutically acceptable acid addition salt thereof. Part (a) of step (5) involves reacting an N-oxide with an isocyanate wherein the isocyanato group is bonded to a hydrolytically active functional group. The term "hydrolytically active functional group" as used herein designates any functional group that is capable of being subjected to a nucleophilic
displacement reaction in step (5) (b) of the Reaction Scheme. Exemplary hydrolytically active functional groups include carbonyl
Figure imgf000013_0001
A particular class of such isocyanates is isocyanates of the formula Ri-X-NCO, wherein Ri is an organic group substantially inert to quinoline N-oxides under the conditions of step (5) (a) and X is a hydrolytically active functional group. Suitable Ri groups are easily selected by those skilled in the art. Preferred groups Ri include alkyl, aryl, alkenyl, and combinations thereof. Particular preferred isocyanates include aroyl isocyanates such as benzoylisoσyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as dichloromethane. The resulting
4-substituted compound of Formula III can be isolated by removal of the solvent.
Step (5) (b) of the Reaction Scheme involves hydrolysis of a compound of Formula III. The term "hydrolysis" as used herein designates not only
nucleophilic displacement with water but also
displacement with other nucleophilic compounds. Such a reaction can be carried out by general methods well known to those skilled in the art, e.g., by heating in the presence of a nucleophilic solvent such as water or a lower alkanol optionally in the presence of a
catalyst such as an alkali metal hydroxide or lower alkoxide. In instances wherein there are hydroxyl protecting groups present in the compound of Formula III, they too can be removed in step (5) (b). A hydroxyl-containing compound of Formula I can be converted or further elaborated by methods well known to those skilled in the art to afford a further compound of Formula I. For example, reaction with thionyl chloride will provide a compound of Formula I wherein Z is chloro. Reaction of this compound with a nucleophile such as sodium azide, pyrrolidine,
methanethiol, or morpholine will afford a compound of Formula I wherein Z is azido, 1-pyrrolidino,
thiomethyl, or 1-morpholino, respectively. Reduction of an azido compound provides a compound of Formula I wherein Z is amino. Such an amino compound can be acylated to form a compound wherein Z is alkylamido.
Some compounds of Formula I can be prepared by a similar reaction scheme wherein the final desired group Z is introduced directly in step (4) and carried on through the process of the invention.
The product compound of Formula I can be isolated by the conventional means disclosed in U.S. Pat. No. 4,689,338 (Gerster), such as, for example, removal of the solvent and recrystallization from an appropriate solvent (e.g., N,N-dimethylformamide) or solvent mixture, or by dissolution in an appropriate solvent (e.g., methanol) and re-precipitation by addition of a second solvent in which the compound is insoluble.
The compounds of Formula I can be used in the form of acid addition salts such as hydrochlorides, dihydrogen sulfates, trihydrogen phosphates, hydrogen nitrates, methane sulfonates and salts of other
pharmaceutically acceptable acids. Pharmaceutically acceptable acid-addition salts of compounds of Formula I are generally prepared by reaction of the respective compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e.g., diethyl ether).
Some of the 1H-imidazo[4,5-c]quinolin-4-amines prepared by the process of this invention are disclosed in U.S. Pat. Nos. 4,689,338 (Gerster) and 4,929,624 (Gerster et al.) as antiviral agents. The process as described above is illustrated in Example 1 below for the synthesis of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The exemplified process affords the final product in a 40% overall yield from 4-hydroxyquinoline.
In the following Examples, all reactions were run with stirring under an atmosphere of dry nitrogen unless otherwise indicated. The particular materials and amounts thereof recited in the Example, as well as other conditions and details, should not be construed to unduly limit the invention.
EXAMPLE 1
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin- 4-amine
Part A
4-Hydroxyquinoline (26.2 g, 0.18 mol) was added to propionic acid (250 mL) and the solution was heated to about 125°C. Nitric acid (16.0 mL of a 70 percent aqueous solution, 0.36 mol) was added dropwise with stirring. When the addition was complete, the mixture was stirred at about 125°C for 10 minutes, then allowed to cool to room temperature. The mixture was diluted with ethanol. The precipitated solid was filtered, washed sequentially with ethanol, water, and ethanol, and dried to afford 3-nitro-4-hydroxyquinoline (27.7 g, 86%) as a light yellow powder. Part B
The compound 3-nitro-4-hydroxyquinoline (19.0 g, 0.10 mol) was suspended in dichloromethane (200 mL). Thionyl chloride (8.1 mL, 0.11 mol) and
N,N-dimethylformamide (8.5 mL, 0.11 mol) were added. The reaction mixture was then heated for 3.5 hours at reflux, during which time a small amount of solid precipitated. The reaction mixture was then cooled to -15°C and a solution of isobutylamine (15.1 mL, 0.15 mol), and triethylamine (20.9 mL, 0.15 mol) in
dichloromethane (100 mL) was added in a slow stream with vigorous swirling. During the addition the temperature of the reaction mixture rose to 20°C. The resulting solution was heated at reflux for 30 minutes, cooled, and the solvent was removed at reduced pressure to afford a yellow solid product. The product was slurried in water, filtered, washed with water, and dried partially. The partially dried product was then slurried in ethanol (75 mL), filtered, washed
successively with a small amount of ethanol and a small amount of diethyl ether, and dried at reduced pressure to afford a yellow crystalline solid product. A second crop of product was obtained by evaporating the ethanol filtrate. The total amount of N-(2-methylpropyl)-3-nitro-4-quinolinamine was 23.3 g.
Part C
N-(2-methylpropyl)-3-nitro-4-quinolinamine (61.3 g, 0.25 mol) was placed in a Paar apparatus along with 5% Pt/C (1.5 g), magnesium sulfate (60 g), ethyl acetate (750 mL), and formic acid (400 mL). The
mixture was placed under a hydrogen atmosphere (about 50 psi) and hydrogenated. The catalyst was removed by filtration and the solvent was evaporated to afford the crude product. The crude product was dissolved in 98% formic acid (400 mL) and refluxed for 1 hour. The resulting solution was evaporated to dryness and the resulting solid was dissolved in ethanol (400 mL). Peroxyacetic acid (63 mL of an acetic acid solution containing 32% peroxyacetic acid based on the total weight of the solution, 0.3 mol) was added and the solution was heated at 56°C for about 0.5 hour. The solution was then cooled and the solvents were removed at reduced pressure. The residue was then
co-evaporated with heptane (3x300 mL) to afford a solid with spectral properties identical to those of an authentic sample of 1-(2-methylpropyl)imidazo[4,5-c]-quinoline-5N-oxide.
Part D
1-(2-Methylpropyl)-1H-imidazo- [4,5-c]quinoline-5N-oxide (7.3 g, 0.0303 mol) was dissolved in dichloromethane (250 mL) and benzoyl isocyanate (5.0 g, 0.0306 mol) was dissolved in
dichloromethane and added to the stirred solution. The reaction solution warmed spontaneously and refluxed briefly. The solution was then refluxed on the steam bath for 15 min and diluted with hexane until turbid. A crystalline solid formed and was filtered from the mixture, washed with dichloromethane/hexane, and dried. A yield of 8.1 g of colorless crystalline solid was obtained. A second crop of 1.4 g was obtained from the filtrate. A combined yield of 9.5 g of N-benzoyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (91.1%) was obtained. Melting point 193°C-196°C.
Analysis Calc'd Found
C 73.23% %C: 73.29
H 5.85% %H: 5.8
N 16.27% %N: 16.3
Part E
N-Benzoyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (5.0 g, 0.0145 mol) and sodium methoxide (10 drops of a 25% by weight solution in methanol) were mixed in methanol (50 mL) and the mixture was heated at reflux for 75 minutes. The mixture was cooled to room temperature, and a solid formed. The solid was filtered from the mixture, washed sequentially with water and methanol, and dried. A crude yield of colorless product of 3.3 g (94.3%) was obtained. Spectral properties of the product
corresponded to those of an authentic sample.
EXAMPLE 2
4-Amino-1-(2-methylpropyl)α-phenyl-1H- imidazo[4,5-c]quinoline-2-methanol
Part A
3-Amino-4-(2-methylpropylamino)quinoline (43.5 g; 0.20 mole) and 300 mL of formic acid were combined and heated on a steam bath for several hours. The reaction mixture was concentrated under vacuum, diluted with water, basified with ammonium hydroxide then extracted twice with ether. The ether extracts were treated with activated charcoal then combined for a total volume of 1200 mL. The volume was reduced to 500 mL, cooled, then filtered to provide 31.1 g of a light green crystalline solid 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline.
1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinoline
(4 g; 0.017 mole) was dissolved in 50 mL of
tetrahydrofuran then cooled to -78°C. A 7.75 mL
portion of n-butyl lithium (2.5 M in hexanes) was added dropwise to the cooled solution. At 15 minutes post addition, benzaldehyde (2.7 mL; 0.027 mole) was added and the reaction mixture was allowed to warm slightly. The reaction was quenched with water then diluted with ethyl ether. The ether was separated, dried with magnesium sulfate then concentrated under vacuum. The resulting residue was purified by silica gel
chromatography using 5% methanol in methylene chloride as the eluent to give an oily yellow solid. This material was recrystallized from methylene
chloride/hexane to provide 1-(2-Methylpropyl)-α-phenyl-1H-imidazo[4,5-c]quinoline-2-methanol as a white crystalline solid, m.p. 160-166°C. Analysis: Calc'd: C, 76.1; H, 6.4; N, 12.7; Found: C, 75.9; H, 6.3; N, 12.7.
Part B
1-(2-Methylpropyl)-α-phenyl-1H-imidazo[4,5-c]-quinoline-2-methanol (3 g; 9 mmole) was dissolved in 50 mL of methylene chloride then combined with acetic anhydride (1.3 mL; 13.5 mmole) and triethylamine (1.6 mL; 11.8 mole) and stirred at room temperature
overnight. The reaction mixture was diluted with methylene chloride, washed sequentially with water and saturated sodium bicarbonate solution, dried over magnesium sulfate and concentrated under vacuum. The resulting residue was purified by silica gel flash chromatography (50% ethyl acetate in methylene chloride as eluent) to provide 1-(2-methylpropyl)-α-phenyl-1H-imidazo[4,5-c]quinoline-2-methyl acetate as a white solid. The structure was confirmed by nuclear magnetic resonance spectroscopy. Part C
1-(2-Methylpropyl)-α-phenyl-1H-imidazo[4,5-c]-quinoline-2-methyl acetate (3 g; 8 mmole) was dissolved in 50 mL of ethyl acetate then combined with peracetic acid (2.2 g; 8.8 mmole) and heated at reflux for about an hour. The reaction mixture was allowed to cool and then was stirred at room temperature for several days. The resulting precipitate was collected, rinsed with ethyl acetate and dried to provide 2.6 g of
2-(α-acetoxybenzyl)-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N oxide as a solid. The structure was confirmed by nuclear magnetic resonance spectroscopy. Part D
2-(α-Acetoxybenzyl)-1-(2-methylpropyl)-1H- imidazo[4,5-c]quinoline 5N oxide (2.6 g; 6.7 mmole) was dissolved in about 40 mL of methylene chloride, combined with benzoyl isocyanate (1.2 g; 7.3 mmole) and heated at reflux for about one hour. The reaction mixture was diluted with methylene chloride, washed with water, dried over magnesium sulfate and
concentrated under vacuum. The residue was taken up in methanol, combined with a catalytic amount of 25% sodium methoxide in methanol, and heated at reflux for several hours. The reaction product was purified by silica gel chromatography using 2-5% methanol in methylene chloride then recrystallized from ethyl acetate-hexane. The recrystallized material was co-evaporated twice with methylene chloride to provide about 0.5 g of 4-amino-1-(2-methylpropyl)-α-phenyl-1H- imidazo[4,5-c]quinoline-2-methanol as a solid, m.p.
125-140°C. Analysis: Calc'd: C, 72.8; H, 6.4; N, 16.2; Found: C, 71.9; H, 5.6; N, 15.6.
EXAMPLE 3
4-Amino-α-(4-chlorophenyl)-1- (2-methylpropyl)-1H-imidazo[4,5-c]quinoline-2-methanol
Part A
Using the method of Example 2, Part A, 2.5 g of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline was reacted with 4-chlorobenzaldehyde to provide 3.1 g of α-(4-chlorophenyl)-1-(2-methylpropyl)-1H-imidazo-[4,5-c]quinoline-2-methanol as a yellow solid. The structure was confirmed by nuclear magnetic resonance spectroscopy.
Part B
Using the method of Example 2, Part B, 2.6 g (7.1 mmole) of α-(4-chlorophenyl)-1H-imidazo- [4,5-c]quinoline-2-methanol was reacted with acetic anhydride to provide α-(4-chlorophenyl)-1- (2-methylpropyl)-1H-imidazo[4,5-c]quinoline-2-methyl acetate as a thick oil. The structure was confirmed by nuclear magnetic resonance spectroscopy.
Part C
Using the method of Example 2 , Part C, 2.9 g (7.1 mmole) of α-(4-chlorophenyl)-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline-2-methyl acetate was oxidized with peracetic acid to provide 2-(α-acetoxy-4-chlorobenzyl)-1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinoline 5N oxide as an oil. Part D
Using the method of Example 2, Part D, 3.3 g (7.8 mmole) of 2-(α-acetoxy-4-chlorobenzyl)-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N oxide was reacted with benzoyl isocyanate then hydrolyzed to provide 0.8 g of 4-amino-α-(4-chlorophenyl)-1- (2-methylpropyl)-1H-imidazo[4,5-c]quinoline-2-methanol as a solid, m.p. 140-145°C. Analysis: Calculated: C, 66.2; H, 5.6; N, 14.7; Found: C, 65.6; H, 5.5; N, 14.4.

Claims

What Is Claimed Is:
1. A process for preparing a 1H-imidazo- [4,5-c]quinolin-4-amine, comprising the steps of:
(i) providing a 1H-imidazo[4,5-c]quinoline
5N-oxide having no functional groups other than the 5N-oxide that are reactive to organic isocyanates;
(ii) reacting the 1H-imidazo[4,5-c]quinoline 5N-oxide from step (i) with an organic isocyanate of the formula Ri-X-NCO, wherein Ri is an organic group substantially inert to quinoline N-oxides and X is a hydrolytically active functional group, to afford a 1H-imidazo[4,5-c]quinoline having a 4-substituent of the formula Ri-X-NH-;
(iii) hydrolysing the product of step (ii) to afford a 1H-imidazo[4,5-c]quinolin-4-amine; and
(iv) isolating the product of step (iii) or a pharmaceutically acceptable acid-addition salt thereof.
2. A process according to Claim 1 for
preparing a compound of Formula I:
Figure imgf000022_0001
wherein
R1 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said
moieties, then the moieties together contain no more than six carbon atoms;
R2 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl;
(phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000024_0002
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, chloro, hydroxy,
1-morpholino, 1-pyrrolidino, and thioalkyl of one to about four carbon atoms;
R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is zero or one, or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of:
(i) providing a compound of Formula II
Figure imgf000024_0001
wherein R, n, and R2 are as defined above with the proviso that Z in R2 is other than amino, substituted amino, or hydroxy, and R5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms;
straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is
substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
(ii) reacting the compound of Formula II with an isocyanate of the formula Ri-X-NCO wherein X is a hydrolytically active functional group and Ri is an organic group substantially inert to quinoline N-oxides to afford a compound of Formula III
Figure imgf000026_0001
wherein X, Ri, R, R2, R5, and n are as defined above with the proviso that Z in R2 is other than amino,
substituted amino, and hydroxyl; and
(iii) hydrolysing the product of step (ii) to provide a compound of Formula I;
(iv) optionally converting or further elaborating the group Z in R2; and
(v) isolating the compound of Formula I from step (iv) or a pharmaceutically acceptable acid addition salt therof.
3. A process according to Claim 2, wherein Ri is alkyl, aryl, alkenyl, or a combination thereof.
4. A process according to Claim 2, wherein X is
Figure imgf000026_0002
5. A process according to Claim 3 , wherein X is
Figure imgf000026_0003
6. A process according to Claim 1 wherein the compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine.
7. A process for preparing a compound of Formula I:
Figure imgf000027_0001
wherein R1 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and
substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms;
straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl) ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
R2 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl; (phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000028_0001
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and Z is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, chloro, hydroxy,
1-morpholino, 1-pyrrolidino, and thioalkyl of one to about four carbon atoms;
R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is zero or one, or a pharmaceutically acceptable acid addition salt thereof, which process comprises the steps of: (i) providing a compound of Formula III
Figure imgf000029_0001
wherein X is a hydrolytically active functional group, Ri is an organic group substantially inert to quinoline N-oxides, R, R2, and n are as defined above with the proviso that Z in R2 is other than amino, substituted amino, and hydroxyl, and R5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and
substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms;
straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is
substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and
(ii) hydrolysing the compound of Formula III to provide a compound of Formula I;
(iii) optionally converting or further
elaborating the group Z in R2; and
(iv) isolating the compound of Formula I from step (iii) or a pharmaceutically acceptable acid addition salt thereof.
8. A process for preparing a
1H-imidazo[4,5-c]quinoline having a 4-substituent of the formula Ri-X-NH-, wherein Ri is an organic group substantially inert to quinoline N-oxides, and X is a hydrolytically active functional group, comprising the steps of:
(i) providing a 1H-imidazo[4,5-c]quinoline 5N-oxide having no functional groups other than the 5N-oxide that are reactive to organic isocyanates; and
(ii) reacting the compound from step (i) with a compound of the formula Ri-X-NCO, wherein Ri and X are as defined above.
9. A process according to Claim 8 for preparing a compound of the formula
Figure imgf000031_0001
wherein
R5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms;
acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl,
(phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
R6 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl;
(phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000032_0001
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and G is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, azido, chloro, 1-morpholino,
1-pyrrolidino, and thioalkyl of one to about four carbon atoms;
R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl, and n is zero or one;
X is a hydrolytically active functional group; and Ri is an organic group substantially inert to quinoline N-oxides, comprising the steps of
(i) providing a compound of Formula II
Figure imgf000033_0002
wherein R, n, R5, and R6 are as defined above;
(ii) reacting the compound of Formula II with an isocyanate of the formula Ri-X-NCO wherein X is a hydrolytically active functional group and Ri is an organic group substantially inert to quinoline
N-oxides.
10. A compound of the formula
Figure imgf000033_0001
wherein X is a hydrolytically active functional group, Ri is an organic group substantially inert to quinoline N-oxides, and wherein
R5 is selected from the group consisting of: straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl
containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms;
acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or aroyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl,
(phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;
R6 is selected from the group consisting of hydrogen; straight chain or branched chain alkyl containing one to about eight carbon atoms; benzyl;
(phenyl) ethyl; and phenyl; the benzyl, (phenyl) ethyl, or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of lower alkyl, lower alkoxy, halogen, and
Figure imgf000035_0002
wherein Ra and Rb are independently selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and G is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, azido, chloro, 1-morpholino,
1-pyrrolidino, and thioalkyl of one to about four carbon atoms;
R is selected from the group consisting of lower alkoxy, halogen, and lower alkyl; and
n is zero or one.
11. A compound according to Claim 10, wherein Ri is alkyl, aryl, alkenyl, or a combination thereof.
12. A compound according to Claim 10, wherein
X is
Figure imgf000035_0001
PCT/US1992/001212 1991-03-01 1992-02-13 PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES WO1992015581A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69213720T DE69213720T2 (en) 1991-03-01 1992-02-13 METHOD FOR PRODUCING IMIDAZO (4,5-c) CHINOLIN-4-AMINES
EP92909690A EP0575549B1 (en) 1991-03-01 1992-02-13 PROCESS FOR IMIDAZO [4,5-c]QUINOLIN-4-AMINES
JP50932392A JP3313708B2 (en) 1991-03-01 1992-02-13 Process for producing imidazo [4,5-C] quinolin-4-amine
AU16993/92A AU657958B2 (en) 1991-03-01 1992-02-13 Process for imidazo(4,5-c)quinolin-4-amines
KR1019930702603A KR100226184B1 (en) 1991-03-01 1992-02-13 Imidazo(4,5,c)quinolin-4-amines and process thereof
CA002104781A CA2104781C (en) 1991-03-01 1992-02-13 Process for imidazo[4,5-c]quinolin-4-amines
NO933105A NO301714B1 (en) 1991-03-01 1993-08-31 Process and intermediate for the preparation of substituted imidazo [4,5-c] quinoline-4-amines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US663,110 1991-03-01
US07/663,110 US5175296A (en) 1991-03-01 1991-03-01 Imidazo[4,5-c]quinolin-4-amines and processes for their preparation

Publications (1)

Publication Number Publication Date
WO1992015581A1 true WO1992015581A1 (en) 1992-09-17

Family

ID=24660514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001212 WO1992015581A1 (en) 1991-03-01 1992-02-13 PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES

Country Status (17)

Country Link
US (1) US5175296A (en)
EP (1) EP0575549B1 (en)
JP (2) JP3313708B2 (en)
KR (1) KR100226184B1 (en)
AT (1) ATE142632T1 (en)
AU (1) AU657958B2 (en)
CA (1) CA2104781C (en)
CZ (1) CZ291368B6 (en)
DE (1) DE69213720T2 (en)
DK (1) DK0575549T3 (en)
ES (1) ES2091463T3 (en)
HU (1) HU218219B (en)
IE (1) IE920524A1 (en)
IL (1) IL100998A (en)
NO (1) NO301714B1 (en)
NZ (1) NZ241645A (en)
WO (1) WO1992015581A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO2001058900A1 (en) * 2000-02-09 2001-08-16 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
US6841678B2 (en) 2002-07-26 2005-01-11 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
US6852861B2 (en) 2002-07-23 2005-02-08 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
EP1609792A1 (en) * 2004-06-24 2005-12-28 Dipharma S.p.A. A process for the preparation of imiquimod and intermediates thereof
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8846710B2 (en) 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CN104402878A (en) * 2014-10-22 2015-03-11 天方药业有限公司 Preparation method of imiquimod
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
JPH09500128A (en) * 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー Imidazo [4,5-c] pyridin-4-amine
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CA2361936C (en) 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
ES2318615T3 (en) * 2001-11-16 2009-05-01 Coley Pharmaceutical Group, Inc. N- (4- (4-AMINO-2-ETIL-1H-IMIDAZO (4,5-C) QUINOLIN-1-IL) BUTIL) METHANOSULPHONAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES ITSELF.
DK1450804T3 (en) * 2001-11-29 2009-01-05 3M Innovative Properties Co Pharmaceutical formula rings comprising an immune response modifier
WO2004080430A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1478327T1 (en) * 2002-02-22 2015-08-31 Meda Ab Method of reducing and treating uvb-induced immunosuppression
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
EP1513524A4 (en) * 2002-06-07 2008-09-03 3M Innovative Properties Co Ether substituted imidazopyridines
DE60335010D1 (en) 2002-08-15 2010-12-30 3M Innovative Properties Co IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co Selective modulation of tlr-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
TW200505458A (en) * 2003-03-07 2005-02-16 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP1617871A4 (en) * 2003-04-10 2010-10-06 3M Innovative Properties Co Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AR044466A1 (en) * 2003-06-06 2005-09-14 3M Innovative Properties Co PROCESS FOR THE PREPARATION OF IMIDAZO [4,5-C] PIRIDIN-4-AMINAS
JP2007500712A (en) * 2003-07-31 2007-01-18 スリーエム イノベイティブ プロパティズ カンパニー Composition for encapsulation and sustained release
EP1651216A2 (en) * 2003-08-05 2006-05-03 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
EP1653914A4 (en) * 2003-08-12 2008-10-29 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
PL1653959T3 (en) * 2003-08-14 2015-10-30 3M Innovative Properties Co Lipid-modified immune response modifiers
CA2551075A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
AU2004268616B2 (en) 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
WO2005029037A2 (en) * 2003-09-17 2005-03-31 3M Innovative Properties Company Selective modulation of tlr gene expression
CA2536530A1 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR20060120069A (en) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
JP2007509987A (en) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー Neutrophil activation by immune response modulator compounds
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co Hydroxylamine substituted imidazo ring compounds
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
TW200533352A (en) * 2003-12-04 2005-10-16 3M Innovative Properties Co Sulfone substituted imidazo ring ethers
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699792A1 (en) * 2003-12-29 2006-09-13 3M Innovative Properties Company Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
AU2005222995B2 (en) 2004-03-15 2010-08-26 3M Innovative Properties Company Immune response modifier formulations and methods
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
JP2008511683A (en) 2004-09-02 2008-04-17 スリーエム イノベイティブ プロパティズ カンパニー 2-Amino 1H-imidazo ring structure and method
JP5209312B2 (en) * 2004-09-02 2013-06-12 スリーエム イノベイティブ プロパティズ カンパニー 1-alkoxy 1H-imidazo ring systems and methods
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
PL1830876T3 (en) * 2004-12-30 2015-09-30 Meda Ab Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP5313502B2 (en) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
CA2602098A1 (en) * 2005-03-14 2006-09-21 Graceway Pharmaceuticals, Llc Method of treating actinic keratosis
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
US7629027B2 (en) * 2005-10-14 2009-12-08 3M Innovative Properties Company Method for making chromonic nanoparticles
US7718716B2 (en) * 2005-10-14 2010-05-18 3M Innovative Properties Company Chromonic nanoparticles containing bioactive compounds
ES2429170T3 (en) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolines substituted with hydroxyl and alkoxy and methods
US20070128291A1 (en) * 2005-12-07 2007-06-07 Tokie Jeffrey H Method and Apparatus for Forming Chromonic Nanoparticles
US7807661B2 (en) * 2005-12-08 2010-10-05 3M Innovative Properties Company Silver ion releasing articles and methods of manufacture
US7323568B2 (en) * 2005-12-12 2008-01-29 Chemagis Ltd. Process for preparing Imiquimod
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007106852A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Substituted fused[1,2]imidazo[4,5-c] ring compounds and methods
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20070275185A1 (en) * 2006-05-23 2007-11-29 3M Innovative Properties Company Method of making ordered nanostructured layers
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
US7659398B2 (en) * 2007-02-14 2010-02-09 Chemagis Ltd. Imiquimod production process
JP2010523595A (en) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー Poly (amino acid) targeting part
JP2011500569A (en) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー Vaccine nanotechnology
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
MX2011008500A (en) * 2009-02-11 2011-09-26 Univ California Toll-like receptor modulators and treatment of diseases.
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
JP6367554B2 (en) 2010-05-26 2018-08-01 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Dosage selection of adjuvanted synthetic nanocarriers
CN103097386A (en) 2010-08-17 2013-05-08 3M创新有限公司 Lipidated immune response modifier compound compositions, formulations, and methods
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CN103702687A (en) 2011-07-29 2014-04-02 西莱克塔生物科技公司 Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
RU2737765C2 (en) 2012-05-04 2020-12-02 Пфайзер Инк. Prostate-associated antigens and immunotherapeutic regimens based on vaccines
CN111511740B (en) 2017-12-20 2023-05-16 3M创新有限公司 Amide substituted imidazo [4,5-C ] quinoline compounds with branched linking groups for use as immune response modifiers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389302A1 (en) * 1989-03-23 1990-09-26 Riker Laboratories, Inc. Olefinic 1H-imidazo [4,5-c]quinolin-4-amines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389302A1 (en) * 1989-03-23 1990-09-26 Riker Laboratories, Inc. Olefinic 1H-imidazo [4,5-c]quinolin-4-amines

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO2001058900A1 (en) * 2000-02-09 2001-08-16 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
US6852861B2 (en) 2002-07-23 2005-02-08 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US7153967B2 (en) 2002-07-23 2006-12-26 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US6841678B2 (en) 2002-07-26 2005-01-11 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
US7166721B2 (en) 2002-07-26 2007-01-23 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Preparation of 1H-imidazo[4,5-C] quinolin 4-amines via novel 1H-imidazo[4,5-c] quinolin 4-cyano and 1H-imidazo[4,5-c] quinolin 4-carboxamide intermediates
US7335772B2 (en) 2002-07-26 2008-02-26 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
EP1609792A1 (en) * 2004-06-24 2005-12-28 Dipharma S.p.A. A process for the preparation of imiquimod and intermediates thereof
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
WO2006098852A3 (en) * 2005-02-23 2007-05-31 3M Innovative Properties Co Hydroxyalkyl substituted imidazoquinolines
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
US8846710B2 (en) 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
CN104402878A (en) * 2014-10-22 2015-03-11 天方药业有限公司 Preparation method of imiquimod
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Also Published As

Publication number Publication date
EP0575549B1 (en) 1996-09-11
NZ241645A (en) 1995-05-26
US5175296A (en) 1992-12-29
NO933105L (en) 1993-08-31
IL100998A0 (en) 1992-11-15
JP3450736B2 (en) 2003-09-29
HU218219B (en) 2000-06-28
HU9302456D0 (en) 1993-11-29
IE920524A1 (en) 1992-09-09
IL100998A (en) 1995-10-31
KR930703317A (en) 1993-11-29
EP0575549A1 (en) 1993-12-29
DE69213720T2 (en) 1997-04-03
JP3313708B2 (en) 2002-08-12
CA2104781C (en) 2002-07-09
DK0575549T3 (en) 1997-02-24
NO301714B1 (en) 1997-12-01
CA2104781A1 (en) 1992-09-02
JPH11269177A (en) 1999-10-05
HUT66968A (en) 1995-01-30
AU657958B2 (en) 1995-03-30
KR100226184B1 (en) 1999-10-15
ES2091463T3 (en) 1996-11-01
CZ178793A3 (en) 1995-05-17
NO933105D0 (en) 1993-08-31
AU1699392A (en) 1992-10-06
CZ291368B6 (en) 2003-02-12
ATE142632T1 (en) 1996-09-15
DE69213720D1 (en) 1996-10-17
JPH06505499A (en) 1994-06-23

Similar Documents

Publication Publication Date Title
CA2104781C (en) Process for imidazo[4,5-c]quinolin-4-amines
EP0553202B1 (en) Process for the preparation of imidazo[4,5-c]quinolin-4-amines
AU673309B2 (en) Intermediates useful in the preparation of 1-substituted, 2-substituted 1H-imidazo(4,5-c)quinolin-4-amines
US6437131B1 (en) Process for preparing imidazoquinolinamines
AU7465896A (en) Process for preparing tetrahydroimidazoquinolinamines
HU223947B1 (en) 1-substituted 1h-imidazo [4,5-c]quinolin-4-amines, intermediate and pharmaceutical compositions
US4474953A (en) Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
EP0544981A2 (en) Naphthyridone carboxylic acid derivatives and antibacterial compositions containing them
HU220667B1 (en) Quinolin derivatives for producing 1- and 2-substituted 1h-imidazo[4,5-c]quinolin-4-amines
IL152040A (en) 4 - triphenylphosphinylamino - 1h - imidazo [4,5-c] quinolines, their preparation and use as intermediates in processes for preparing 1h - imidazo [4,5-c] quinolin - 4 - amines
IE83826B1 (en) Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CS HU JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2104781

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992909690

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1993-1787

Country of ref document: CZ

Ref document number: 1019930702603

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1992909690

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1993-1787

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1992909690

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1993-1787

Country of ref document: CZ